Hematology-Oncology
Latest news
316 articles · 20 / page
Post‑transplant Cyclophosphamide with Sirolimus/Cyclosporine Dramatically Lowers Chronic GVHD After Unrelated Donor PBSC Transplant Without Raising Relapse Risk
In a randomized Phase II trial, replacing MMF with post‑transplant cyclophosphamide (PTCy) alongside sirolimus and cyclosporine in unrelated donor PBSC transplants markedly lowered chronic GVHD and improved 1‑year chronic GVHD‑free relapse‑
Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial
In the randomized, double‑blind phase II QUIWI trial, adding quizartinib to standard induction/consolidation chemotherapy and single‑agent maintenance significantly improved event‑free survival and overall survival for adults 18–70 years wi
Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis
The 24‑month final analysis of the phase III REACH2 trial shows ruxolitinib produced longer failure‑free survival, improved median overall and event‑free survival, and a longer duration of response versus best available therapy (BAT) in pat
Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma
Five-year outcomes from ZUMA-5 show axi-cel produces high response rates in relapsed/refractory indolent NHL, with 75% CR, median PFS ~62 months, durable remissions linked to early CAR T expansion and naïve T-cell product phenotype, and an
AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data
Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and sho
Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable
Withholding Two Daunorubicin Doses in Induction Preserves Outcomes and Lowers Fungal Risk in Favorable-Risk Pediatric B-ALL
In children with favorable B-lineage ALL, omission of two daunorubicin doses late in induction was noninferior for 5-year EFS and OS and associated with fewer invasive fungal infections, supporting reduced anthracycline exposure in selected
Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial
Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.
AL-ISS: A New Staging System Identifies an Ultra‑Poor‑Risk Stage (IIIC) in Contemporary AL Amyloidosis
The AL International Staging System (AL-ISS) integrates cardiac biomarkers and echocardiographic longitudinal strain to refine prognosis in systemic AL amyloidosis and define an ultra‑poor‑risk Stage IIIC with median survival of 7 months de
Pirtobrutinib Matches and May Surpass Ibrutinib in BTKi‑Naïve CLL/SLL: First Randomized Head‑to‑Head Results with Improved Cardiac Safety
In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hyper
Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
Preoperative Anaemia Is Common and Multifactorial: Iron Deficiency Dominates but B12 and Folate Shortfalls Matter
The ALICE international cohort found 31.7% prevalence of preoperative anaemia in major surgery patients; iron deficiency accounted for 55% of confirmed causes, with notable contributions from vitamin B12 and folate deficiencies. Broader pre
Hidden Burden: Nearly 1 in 10 Adolescents and Young Adults Develop Metastatic Recurrence — Survival Often Worse Than De Novo Metastasis
A California cohort study found a 5-year cumulative incidence of metastatic recurrence of 9.5% among adolescents and young adults (AYAs) initially diagnosed with nonmetastatic cancer; recurrence risk and post-recurrence survival varied mark
Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety
In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible
Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results
SURPASS‑ET, a phase 3 randomized trial, showed ropeginterferon alfa‑2b achieved durable ELN responses in 43% of hydroxyurea‑intolerant/refractory ET patients with leukocytosis versus 6% with anagrelide, with a favorable safety profile and f
How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy
A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.
Atorvastatin Preserves Aortic Elasticity During Anthracycline Chemotherapy: Secondary Analysis of STOP‑CA
In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy
Fixed‑Duration Venetoclax After RBAC Improves 2‑Year PFS in High‑Risk Older Mantle Cell Lymphoma: Final Results of the FIL_V‑RBAC Phase 2 Study
In a multicentre, risk‑adapted phase 2 trial, adding fixed‑duration venetoclax after rituximab‑bendamustine‑cytarabine (RBAC) produced a 2‑year progression‑free survival of 60% in older patients with high‑risk mantle cell lymphoma (MCL). To
Browse by specialty
Open language-specific specialty feeds and department pages.